CVS Health Co. (NYSE:CVS) Expected to Announce Quarterly Sales of $76.46 Billion

Analysts forecast that CVS Health Co. (NYSE:CVSGet Rating) will report sales of $76.46 billion for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for CVS Health’s earnings. The lowest sales estimate is $76.13 billion and the highest is $76.70 billion. CVS Health reported sales of $72.62 billion in the same quarter last year, which indicates a positive year over year growth rate of 5.3%. The company is scheduled to announce its next quarterly earnings report on Monday, January 1st.

On average, analysts expect that CVS Health will report full-year sales of $307.26 billion for the current financial year, with estimates ranging from $306.38 billion to $308.00 billion. For the next fiscal year, analysts expect that the company will report sales of $321.25 billion, with estimates ranging from $318.72 billion to $323.94 billion. Zacks Investment Research’s sales calculations are an average based on a survey of analysts that that provide coverage for CVS Health.

CVS Health (NYSE:CVSGet Rating) last issued its quarterly earnings data on Wednesday, May 4th. The pharmacy operator reported $2.22 EPS for the quarter, beating the consensus estimate of $2.14 by $0.08. CVS Health had a return on equity of 15.15% and a net margin of 2.71%. The company had revenue of $76.83 billion for the quarter, compared to analyst estimates of $75.30 billion. During the same period last year, the company earned $2.04 earnings per share. CVS Health’s quarterly revenue was up 11.2% compared to the same quarter last year.

Several analysts have commented on the company. Sanford C. Bernstein raised their price objective on CVS Health from $111.00 to $116.00 in a report on Tuesday, January 11th. Edward Jones raised CVS Health from a “hold” rating to a “buy” rating in a research note on Monday, January 10th. BMO Capital Markets lifted their price target on CVS Health from $108.00 to $120.00 in a research note on Thursday, February 10th. Robert W. Baird lifted their price objective on CVS Health from $107.00 to $110.00 in a research report on Wednesday, January 12th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on CVS Health from $110.00 to $113.00 in a research report on Thursday. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, CVS Health currently has an average rating of “Buy” and a consensus price target of $114.90.

Shares of CVS opened at $97.73 on Friday. The company has a current ratio of 0.88, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. CVS Health has a 12 month low of $79.33 and a 12 month high of $111.25. The stock’s 50 day moving average is $103.63 and its two-hundred day moving average is $100.51. The firm has a market cap of $128.34 billion, a P/E ratio of 16.40, a PEG ratio of 1.54 and a beta of 0.78.

The business also recently declared a quarterly dividend, which was paid on Monday, May 2nd. Shareholders of record on Friday, April 22nd were issued a dividend of $0.55 per share. The ex-dividend date of this dividend was Thursday, April 21st. This represents a $2.20 annualized dividend and a yield of 2.25%. CVS Health’s dividend payout ratio (DPR) is 36.91%.

In other CVS Health news, Director Edward J. Ludwig acquired 1,000 shares of the company’s stock in a transaction dated Thursday, February 10th. The shares were acquired at an average price of $105.90 per share, for a total transaction of $105,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Daniel P. Finke sold 55,359 shares of the stock in a transaction dated Monday, April 4th. The shares were sold at an average price of $100.13, for a total value of $5,543,096.67. Following the completion of the transaction, the executive vice president now owns 3,098 shares in the company, valued at approximately $310,202.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,283 shares of company stock worth $8,376,142. 0.69% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. West Bancorporation Inc. purchased a new position in shares of CVS Health in the 4th quarter valued at about $25,000. Macroview Investment Management LLC increased its holdings in shares of CVS Health by 128.3% in the 1st quarter. Macroview Investment Management LLC now owns 242 shares of the pharmacy operator’s stock valued at $25,000 after acquiring an additional 136 shares during the last quarter. Bell Investment Advisors Inc purchased a new position in CVS Health during the 3rd quarter worth approximately $26,000. Claremont Financial Group Inc. purchased a new position in CVS Health during the 4th quarter worth approximately $26,000. Finally, Stuart Chaussee & Associates Inc. grew its stake in CVS Health by 123.0% during the 1st quarter. Stuart Chaussee & Associates Inc. now owns 310 shares of the pharmacy operator’s stock worth $31,000 after buying an additional 171 shares during the last quarter. Institutional investors and hedge funds own 78.00% of the company’s stock.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Recommended Stories

Get a free copy of the Zacks research report on CVS Health (CVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.